VENUS REMEDIES
Quarterly Results Analysis [Mar2025]
VENUS REMEDIES Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹195 Cr | ₹177 Cr | ₹167 Cr | ₹109 Cr | ₹195 Cr | ₹143 Cr | ₹168 Cr | ₹95 Cr |
Expenses | ₹166 Cr | ₹159 Cr | ₹163 Cr | ₹97 Cr | ₹176 Cr | ₹131 Cr | ₹150 Cr | ₹85 Cr |
Operating Income | ₹29 Cr | ₹18 Cr | ₹5 Cr | ₹11 Cr | ₹19 Cr | ₹12 Cr | ₹18 Cr | ₹10 Cr |
Other Income | ₹7 Cr | ₹2 Cr | ₹11 Cr | ₹2 Cr | ₹4 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹6 Cr | ₹8 Cr |
Profit Before Tax | ₹31 Cr | ₹25 Cr | ₹9 Cr | ₹7 Cr | ₹17 Cr | ₹8 Cr | ₹14 Cr | ₹5 Cr |
Profit After Tax | ₹21 Cr | ₹20 Cr | ₹4 Cr | ₹1 Cr | ₹11 Cr | ₹7 Cr | ₹10 Cr | ₹1 Cr |
EPS | ₹15.71 | ₹14.66 | ₹2.63 | ₹0.91 | ₹7.86 | ₹5.12 | ₹7.43 | ₹0.88 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | -4.1% | 46.9% | 41.7% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.9% | 17.2% |
DIVIS LABORATORIES | 1.5% | 10.4% | 51.9% |
CIPLA | 2.3% | 1.9% | 2.8% |
TORRENT PHARMACEUTICALS | 1.4% | 1.3% | 17% |
DR REDDYS LABORATORIES | 5.7% | 14.1% | 15.2% |
MANKIND PHARMA | 0.2% | -2.4% | 12.5% |
ZYDUS LIFESCIENCES | 5.1% | 10.9% | -4.4% |
LUPIN | 2% | -2.2% | 27.9% |
VENUS REMEDIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 10.24 % |
Y-o-Y | -0.10 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹195 Cr | 10.24 | |
Dec2024 | ₹177 Cr | 5.62 | |
Sep2024 | ₹167 Cr | 54.18 | |
Jun2024 | ₹109 Cr | -44.35 | |
Mar2024 | ₹195 Cr | 36.08 | |
Dec2023 | ₹143 Cr | -14.49 | |
Sep2023 | ₹168 Cr | 76.27 | |
Jun2023 | ₹95 Cr | - |
VENUS REMEDIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 57.95 % |
Y-o-Y | 48.87 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹29 Cr | 57.95 | |
Dec2024 | ₹18 Cr | 273.93 | |
Sep2024 | ₹5 Cr | -56.39 | |
Jun2024 | ₹11 Cr | -42.20 | |
Mar2024 | ₹19 Cr | 61.79 | |
Dec2023 | ₹12 Cr | -32.17 | |
Sep2023 | ₹18 Cr | 70.67 | |
Jun2023 | ₹10 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 43.26 % |
Y-o-Y | 49.00 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 14.87% | 43.26 | |
Dec2024 | 10.38% | 254.27 | |
Sep2024 | 2.93% | -71.75 | |
Jun2024 | 10.37% | 3.91 | |
Mar2024 | 9.98% | 18.95 | |
Dec2023 | 8.39% | -20.70 | |
Sep2023 | 10.58% | -3.20 | |
Jun2023 | 10.93% | - |
VENUS REMEDIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 7.14 % |
Y-o-Y | 99.81 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹21 Cr | 7.14 | |
Dec2024 | ₹20 Cr | 458.40 | |
Sep2024 | ₹4 Cr | 187.70 | |
Jun2024 | ₹1 Cr | -88.39 | |
Mar2024 | ₹11 Cr | 53.43 | |
Dec2023 | ₹7 Cr | -31.09 | |
Sep2023 | ₹10 Cr | 742.37 | |
Jun2023 | ₹1 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -2.80 % |
Y-o-Y | 99.81 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 10.77 % | -2.80 | |
Dec2024 | 11.08 % | 427.62 | |
Sep2024 | 2.1 % | 87.50 | |
Jun2024 | 1.12 % | -79.22 | |
Mar2024 | 5.39 % | 12.76 | |
Dec2023 | 4.78 % | -19.39 | |
Sep2023 | 5.93 % | 378.23 | |
Jun2023 | 1.24 % | - |
VENUS REMEDIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 7.16 % |
Y-o-Y | 99.87 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹15.71 | 7.16 | |
Dec2024 | ₹14.66 | 457.41 | |
Sep2024 | ₹2.63 | 189.01 | |
Jun2024 | ₹0.91 | -88.42 | |
Mar2024 | ₹7.86 | 53.52 | |
Dec2023 | ₹5.12 | -31.09 | |
Sep2023 | ₹7.43 | 744.32 | |
Jun2023 | ₹0.88 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD